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Abstract Falciparum malaria is clinically heterogeneous and the relative contribution of parasite
and host in shaping disease severity remains unclear. We explored the interaction between
inflammation and parasite variant surface antigen (VSA) expression, asking whether this relationship
underpins the variation observed in controlled human malaria infection (CHMI). We uncovered
marked heterogeneity in the host response to blood challenge; some volunteers remained
quiescent, others triggered interferon-stimulated inflammation and some showed transcriptional
evidence of myeloid cell suppression. Significantly, only inflammatory volunteers experienced
hallmark symptoms of malaria. When we tracked temporal changes in parasite VSA expression to
ask whether variants associated with severe disease rapidly expand in naive hosts, we found no
transcriptional evidence to support this hypothesis. These data indicate that parasite variants that
dominate severe malaria do not have an intrinsic growth or survival advantage; instead, they
presumably rely upon infection-induced changes in their within-host environment for selection.
Introduction
There is enormous diversity in the human response to identical immune challenge. This variation is
currently being interrogated in large cohorts of healthy volunteers to pinpoint the genetic and non-
genetic factors that dictate human immune decision-making (Bakker et al., 2018; Brodin et al.,
2015; Li et al., 2016; Patin et al., 2018; Piasecka et al., 2018; Ter Horst et al., 2016). Controlled
human malaria infection (CHMI) provides a well-established challenge model in which to examine
immune variation in vivo, and heterogeneity in the host response to Plasmodium falciparum is well-
recognised (Roestenberg et al., 2012; Yap et al., 2020). Prior work suggests a dichotomy in
immune decision-making with some individuals triggering an inflammatory response, which is charac-
terised by high circulating levels of IFNg, whilst others mount an alternative response distinguished
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by the early release of TGFb and suppression of IFNg signalling (de Jong et al., 2020; Harpaz et al.,
1992; Walther et al., 2005; Walther et al., 2006). The precise mechanisms underpinning these
divergent responses remain unknown.
Genome-wide transcriptional profiling has the potential to map immune decision-making in
unprecedented detail and previous CHMI studies have revealed an upregulation of genes associated
with pathogen detection, NFkB activation, and IFNg signalling consistent with a systemic inflamma-
tory response (Ockenhouse et al., 2006; Tran et al., 2019; Tran et al., 2016). A transcriptional sig-
nature of an alternative immune response has not been described in naive hosts. Nevertheless,
these prior studies were primarily designed to measure shared or common signatures of infection,
potentially masking variation between volunteers. Only one study (Burel et al., 2017) has specifically
investigated transcriptional variation in CHMI and it reported two distinct outcomes based on host
microRNA profiles; notably, the authors were able to correlate the induction of three specific miR-
NAs with a lower parasite burden suggesting that events early in infection may have important
downstream consequences. Identifying the sources of immune variation may therefore reveal some
of the factors that underpin the clinical heterogeneity of falciparum malaria. In this context, direct
intravenous challenge with blood-stage parasites provides a unique opportunity to assess the contri-
bution of host-intrinsic mechanisms of variation as it ensures all volunteers receive an identical
immune challenge (Duncan and Draper, 2012).
The potential role of parasite factors in influencing immune variation has not yet been explored in
CHMI. Expression of a subset of parasite variant surface antigens (VSA) known as group A and DC8
var genes is associated with severe malaria in both children and adults (Duffy et al., 2019;
Jespersen et al., 2016; Kyriacou et al., 2006; Lavstsen et al., 2012; Tonkin-Hill et al., 2018;
Warimwe et al., 2012). These virulence-associated genes encode PfEMP1 adhesion molecules that
mediate sequestration of infected red cells in the microvasculature. Group A/DC8-expressing para-
sites are thought to be more pathogenic than those expressing other var types (groups B and C)
and can bind the endothelium with high affinity in sensitive sites, such as brain (Jensen et al., 2020).
It is unknown whether expression of these variants can influence the immune response, for example
by causing dysregulated activation that leads to widespread collateral tissue damage. Or conversely,
whether inflammation might preferentially support the survival and expansion of these variants by
upregulating their binding sites on the endothelium.
It has been observed in previous CHMI studies that parasites transcribe a broad array of var
genes in naive hosts, with predominant expression of group B variants and no marked differences
between volunteers (Bachmann et al., 2019; Bachmann et al., 2016). Indeed, we have shown that
mosquitoes reset malaria parasites to ensure diverse expression of their VSA repertoire at the start
of the blood cycle (Spence et al., 2013). It therefore remains unclear how group A and DC8 var
genes come to dominate the PfEMP1 landscape in severe malaria. Antibody-mediated clearance of
parasites expressing group B variants is a possible explanation, but is unlikely because severe
malaria develops in hosts with low or absent immunity during their first few infections of life
(Gonçalves et al., 2014). It has instead been suggested that parasites expressing group A/DC8 var
genes rapidly and preferentially expand because they have an intrinsic growth and/or survival advan-
tage in naive hosts (Abdi et al., 2017; Bull et al., 2000; Jensen et al., 2004). This may be a conse-
quence of enhanced cytoadherence (reducing their mechanical clearance in the spleen), rosetting
(increasing their re-invasion efficiency) or specificity for tissues that are better able to support their
maturation (decreasing cycle length). This explanation is widely accepted but is not based on sub-
stantial evidence.
In this study, we have used a blood challenge model to investigate host-intrinsic variation in the
immune response to falciparum malaria and examined the interplay between parasite and host fac-
tors in shaping outcome of infection. This model has the advantage that an identical immune chal-
lenge is given to all volunteers and furthermore transcriptional profiling can be carried out on
parasites at the start and end of infection to track changes in VSA expression through time. We set
out to test the specific hypotheses that a, expression of group A and DC8 var genes would preferen-
tially increase as the infection progressed and b, there would be a measurable relationship between
inflammation and parasite VSA expression, which would shape the clinical outcome of infection.
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Results
Immune variation in falciparum malaria
To explore host-intrinsic variation in the immune response to P. falciparum, a cohort of 14 malaria-
naive volunteers were infected with an equal number of blood-stage parasites (clone 3D7) by direct
intravenous inoculation (Supplementary file 1). This enabled the pathogenic blood cycle to be initi-
ated in every volunteer within a 30-min window (Payne et al., 2016). Systemic changes in the host
response were then captured through time by transcriptionally profiling whole blood every 48 hr
from the day before infection until the day of diagnosis (the point of drug treatment). This time-point
varied between volunteers, occurring 7.5–10.5 days post-infection when two out of three diagnostic
criteria were met (positive thick blood smear and/or parasite density >500 parasites ml 1 by qPCR
and/or symptoms consistent with malaria). To reveal the diversity of responses within our cohort,
each volunteer’s time-course was analysed independently by tracking their dynamic changes in gene
expression as the infection progressed. Importantly, this approach does not assume shared features
between individuals, nor does it bias against uncommon (or rare) responses.
As a first step, we measured the variance of every gene through time and visualised the 100 pro-
tein-coding genes with highest variance in each volunteer (Figure 1—source data 1). To control for
baseline variation in gene expression, uninfected control volunteers were also analysed. We found
that variance in one third of infected volunteers (4/14) was comparable to the uninfected control
group, suggesting these four volunteers did not respond to infection (Supplementary file 2). To
explore this further, we merged the top 100 gene lists from all infected volunteers to produce a sin-
gle non-redundant list of the most dynamically expressed protein-coding genes across the cohort
(n = 517 unique genes, henceforth called the 517-gene superset); we could then directly compare
the transcriptional response between individuals. Accordingly, we performed a principal component
analysis (PCA) of these genes through time, and for each volunteer we determined the Euclidean dis-
tance travelled to quantify the magnitude of their response (Figure 1—source data 1 and
Supplementary file 2). Using the variance and distance travelled metrics, we then set two thresholds
to identify volunteers that triggered a measurable response to blood challenge (see
Materials and methods); four volunteers failed to cross both thresholds (v018, v012, v208, and v020)
and were therefore grouped and labelled unresponsive. A pairwise comparison between the diagno-
sis and pre-infection samples obtained from these four volunteers confirmed that there were zero
differentially expressed genes in this group (adj p<0.05). Immune quiescence is therefore a common
outcome of controlled human malaria infection.
In contrast, variance (Figure 1—source data 1) and distance travelled (Figure 1—figure supple-
ment 1) both suggested that the remaining 10 volunteers made a robust response to infection
(Supplementary file 2). And when we clustered and visualised the 517-gene superset expression
data we found that these volunteers could separate easily into two groups according to whether
they up- or downregulated gene expression at diagnosis (Figure 1 and Figure 1—source data 2).
Based on this observation, we grouped the eight volunteers who upregulated gene clusters 2 and 4
and performed a pairwise comparison between their diagnosis and pre-infection samples; we uncov-
ered 2028 differentially expressed genes (adj p<0.05) (Supplementary file 3). To gain insight into
the biological functions of this response, we used ClueGO (Bindea et al., 2009; Mlecnik et al.,
2014) to first identify the significant GO terms associated with these genes and then place them
into a functionally organised non-redundant gene ontology network. ClueGO uncovered 217 GO
terms across 34 functional groups (Supplementary file 4); the most significant groups related to
interferon signalling, activation of myeloid cells, production of inflammatory molecules, and activa-
tion of T cells (Figure 2a–b). These terms all indicate systemic interferon-stimulated inflammation (a
well-described host response to malaria in mouse and human studies [Montes de Oca et al., 2016;
Spaulding et al., 2016; Yu et al., 2016]) and we therefore labeled this group inflammatory. We then
biologically validated ClueGO’s in silico finding by measuring the plasma concentrations of two
interferon-stimulated chemokines, CXCL9 and CXCL10. These chemokines are primarily produced
by myeloid cells and specifically function to recruit and activate T cells (Groom and Luster, 2011).
We found a > 2-fold increase in one or both of these chemokines at diagnosis in every volunteer in
this group but no other volunteer (Figure 2c).
The final two volunteers were also grouped (and given the suppressor tag) based on their appar-
ent downregulation of clusters 1 and 3 at diagnosis (Figure 1). Significantly, a pairwise comparison
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between their diagnosis and pre-infection samples revealed a core signature of 77 genes that were
differentially expressed in response to blood challenge (adj p<0.05, Supplementary file 5). The
majority of these genes (62/77) were downregulated and crucially >85% were unique to this group,
including key regulators of monocyte and neutrophil differentiation (Csf3r) and recruitment and acti-
vation (Cxcl7, Cxcr2, Clec4e, Clec7a, and Mnda, Figure 2d). A direct pairwise comparison between
the inflammatory and suppressor groups confirmed that each of these six immune genes was
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Figure 1. Immune variation in falciparum malaria. Log2 expression values of 517 protein-coding genes in whole blood during infection. Genes (rows)
are ordered by hierarchical clustering whereas whole blood samples (columns) are ordered by volunteer and time-point (pre-infection to diagnosis, left
to right). Arrows start from the pre-infection sample and volunteers are grouped by host response. Uninfected controls demonstrate minimal within-
host variation in expression of these genes. Median sample number per volunteer = 6.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. An identical immune challenge leads to diverse outcomes in falciparum malaria.
Source data 2. Log2 transformed expression values of the 517-gene superset in whole blood during infection.
Figure supplement 1. Immune quiescence is a common early outcome of infection.
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Figure 2. Interferon-stimulated inflammation is the dominant response to blood-stage infection. (A) Gene ontology network of 2028 genes differentially
expressed at diagnosis in the inflammatory group. Each node represents a significantly enriched GO term (adj p<0.05) and node size is determined by
significance (bigger nodes have lower p values). Nodes are interconnected according to their relatedness (kappa score >0.4) and grouped if they are
connected and share >40% genes. Each functional group is then given a unique colour and the leading GO term in the top 12 groups is highlighted.
Figure 2 continued on next page
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differentially expressed at diagnosis, together with a further 887 genes (adj
p<0.05, Supplementary file 6). Evidently, these host response profiles do not overlap and instead
likely represent distinct in vivo outcomes of immune decision-making. Nevertheless, a much larger
sample size would be required to fully elucidate immune suppression as an alternative response to
P. falciparum.
Collectively, these data reveal marked variation in the human immune response to falciparum
malaria with at least three possible outcomes of blood-stage infection – immune quiescence, inter-
feron-stimulated inflammation, and suppression of myeloid-associated gene expression.
Sporozoites have a limited role in shaping the host response to blood-
stage infection
We next explored the influence of the pre-erythrocytic-stages of infection on the immune response
to blood-stage parasites. Whilst blood challenge uses a recently mosquito-transmitted parasite line
(< 3 blood cycles from liver egress [Cheng et al., 1997]) this model nevertheless bypasses the skin
and liver stages, which have been proposed to elicit regulatory mechanisms that could modify the
subsequent immune response to blood-stage infection (Guilbride et al., 2010). We therefore inocu-
lated five additional malaria-naive volunteers with the same parasite genotype but this time by the
natural route of infection, mosquito bite (Supplementary file 1). As before, we transcriptionally pro-
filed whole blood from the day before infection until diagnosis (day 11), including the final day of
liver-stage infection (day 6). And once more, every volunteer was analysed independently this time
using EdgeR to identify highly dispersed genes within each time-course (see
Materials and methods). After merging these lists, we produced a single non-redundant list of the
most dynamically expressed genes across the mosquito challenge cohort (n = 117 unique genes,
henceforth called the 117-gene superset) (Supplementary file 7). When we clustered and visualised
the expression data within this superset we found that 116 out of 117 genes were upregulated exclu-
sively during the blood cycle (Figure 2—figure supplement 1a–b). And when we examined the bio-
logical functions of these genes ClueGO identified response to interferon gamma (GO: 0034341) as
the most significantly enriched GO term (Supplementary file 8). Notably, this was also the most sig-
nificant GO term in inflammatory volunteers infected by blood challenge (Supplementary file 4),
indicating concordance between the two infection models. In agreement, 19 of the 21 genes that
displayed the highest fold change in inflammatory volunteers (blood challenge) were also upregu-
lated in the 117-gene superset (mosquito challenge, Supplementary file 7). And at protein level,
high circulating levels of CXCL10 were detectable at diagnosis in four of the five volunteers infected
by mosquito bite (Figure 2—figure supplement 1c). Our data therefore demonstrate that inter-
feron-stimulated inflammation is the dominant human response to blood-stage parasites regardless
of the route of infection. Furthermore, our data fail to provide compelling evidence of a systemic
transcriptional response to liver-stage infection in human malaria (Figure 2—figure supplement 1b).
Taken together, these findings indicate that the pre-erythrocytic-stages of infection may have a lim-
ited role in shaping the immune response during the pathogenic blood cycle.
Systemic inflammation coincides with the onset of clinical symptoms
We therefore moved on to investigate the factors that influence human immune variation in the
blood challenge model and the consequences of these divergent paths. In the first instance, we
Figure 2 continued
Two GO terms of interest, which are not part of any functional group, are also shown in italics. (B) The proportion of GO terms in each of the top 12
functional groups; collectively, these account for two thirds of all significantly enriched GO terms in inflammatory volunteers. (C) Plasma concentration
of interferon alpha and gamma and interferon-stimulated chemokines (CXCL9 and CXCL10) during infection. One line represents one volunteer (no
data for v020) and lines are colour-coded by host response. For each volunteer, all data points are normalised to their own baseline (day  1); horizontal
green lines represent a twofold increase or decrease compared to baseline. (D) Log2 fold-change of nine immune genes involved in myeloid cell
differentiation and activation in whole blood at diagnosis. Data are presented relative to pre-infection samples and all genes are significantly
downregulated in the two suppressor volunteers (adj p<0.05).
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Sporozoites do not trigger a systemic transcriptional response in human malaria.
Milne, Ivens, Reid, et al. eLife 2021;10:e62800. DOI: https://doi.org/10.7554/eLife.62800 6 of 31
Research article Immunology and Inflammation Microbiology and Infectious Disease
asked whether the rate of parasite replication could shape the host response to infection; after all, a
simple assumption might be that inflammation is triggered by fast-growing parasites. The parasite
multiplication rate (PMR, modelled from the qPCR data [Payne et al., 2016]) varied considerably
between volunteers (range 6.7–12.8) despite every individual receiving an equal number of infected
red cells (Supplementary file 1). However, the parasite multiplication rate of the inflammatory group
was not significantly different to that of unresponsive or suppressor hosts (Figure 3a–b) and there-
fore appears to have little bearing on the outcome of immune decision-making. Inflammatory volun-
teers did, however, tend to have a longer course of infection (Figure 3a) and hence the parasite
burden at diagnosis was higher for the inflammatory group (median 30,309 parasites ml 1, range
9133–273,247) than the rest of the cohort (median 7899 parasites ml 1, range 1440–19,670) (Mann
Whitney test, p=0.02). Parasite burden may therefore promote an inflammatory response in this chal-
lenge model but cannot fully explain it; for example, 2/4 unresponsive volunteers (v018 and v020)
had parasite densities that were comparable to 4/8 inflammatory volunteers at diagnosis (v017,
v027, v026, and v106, Supplementary file 1). Our data therefore support previous observations that
the parasite density threshold required to trigger inflammation is highly variable between individuals
(Gatton and Cheng, 2002; Molineaux et al., 2002).
We next set out to ask whether immune variation had clinical consequences. Symptomatology
was scored throughout infection with adverse events graded as absent (0), mild (1), moderate (2), or
severe (3). Volunteers in the unresponsive and suppressor groups were essentially asymptomatic at
diagnosis, whereas inflammatory volunteers exhibited more frequent and/or severe adverse events,
including fever (Figure 3—figure supplement 1 and Figure 3—figure supplement 2a). When we
then calculated a cumulative clinical score for each volunteer (by summing all adverse events
throughout infection) we found a strong positive correlation between symptoms and the intensity of
inflammation (Figure 3c). In contrast, there was no correlation between clinical score and parasite
multiplication rate (Figure 3d). We then measured circulating levels of Angiopoietin-2, a biomarker
of endothelium dysfunction and indicator of disease severity (Yeo et al., 2008); only one volunteer
displayed elevated levels of Angiopoietin-2 (Figure 3—figure supplement 2b) and this individual
was the most inflammatory host in the cohort (based on upregulation of plasma CXCL10 and IFNg).
What’s more, haematological analysis revealed that only inflammatory volunteers experienced acute
lymphopenia, a conserved hallmark of clinical malaria (Figure 3—figure supplement 2c–
d; Hviid et al., 1997). Symptomatology is therefore not driven by the rate of parasite replication in
controlled human malaria infection. Instead, clinical outcome seems to depend upon the intensity of
inflammation, which varies widely between hosts.
In light of these findings, we examined the potential impact of inflammation on host metabolism
to better resolve the consequences of immune variation. Here, we used an LC-MS-based metabolo-
mics platform to measure changes in circulating metabolites during infection, and applied range-
scaling to ensure all metabolites (and their temporal fluctuations) were equally weighted (van den
Berg et al., 2006). When we compared the three most inflammatory and symptomatic volunteers to
unresponsive and suppressor hosts we could find no metabolic signature of inflammation that was
robust to multiple testing (zero metabolites with an FDR-corrected p value < 0.1). On the other
hand, if we simply considered all volunteers as a single group and compared their post-infection
time-points (day 8 and diagnosis) against pre-infection samples we could identify a conserved and
persistent signature of blood-stage infection (Figure 3—figure supplement 3). This was character-
ised by increased adenosine (promotes vasodilation [Ralevic and Dunn, 2015]), choline depletion
(supports parasite membrane synthesis [Witola and Ben Mamoun, 2007]) and reduced lysoPC (indu-
ces gametocytogenesis [Brancucci et al., 2017, Figure 3e–f]). Evidently, volunteers who are immune
quiescent are nevertheless metabolically responsive to P. falciparum, and their response is indistin-
guishable from inflammatory hosts.
All together, these data reveal that immune decision-making, systemic metabolism and parasite
replication all operate independently in the early stages of the blood cycle. And they further reveal a
clear relationship between the intensity of inflammation and symptomatology in falciparum malaria.
Parasite variants associated with severe disease do not rapidly expand
in naive hosts
To investigate the origin of immune variation and gain further insight into the factors that can shape
outcome of infection we measured parasite VSA expression. To this end, we applied ultra-low input
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Figure 3. Systemic inflammation coincides with the onset of clinical symptoms. (A) Parasite growth curves colour-coded by host response; each line
represents one volunteer. Blood samples were collected every 12 hr for qPCR analysis of circulating parasite density and the horizontal green line
represents the lower limit of quantification (20 parasites ml 1). (B) Parasite multiplication rates colour-coded by host response; each dot represents one
volunteer and shaded areas show the mean value. A Mann Whitney test was used to ask whether the parasite multiplication rate observed in the
inflammatory group was different to all other volunteers (p value is shown). (C and D) Linear regression of CXCL10 (C) or parasite multiplication rate (D)
plotted against clinical score (the sum of adverse events during infection). CXCL10 fold-change measures plasma concentration at diagnosis over
Figure 3 continued on next page
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RNA-sequencing methodology to parasites isolated during CHMI and mapped their transcriptional
profiles from the start to end of infection. In the first instance, we examined the hierarchy of var
gene expression in the inoculum used for blood challenge; this derived from a single malaria-
infected volunteer infected by mosquito bite and was cryopreserved ex vivo (without culture) after
just three cycles of asexual replication (Cheng et al., 1997). Although each individual blood-stage
parasite will only transcribe a single var gene (Freitas-Junior et al., 2005) the parasite population as
a whole can express many different variants within a host. In agreement, we found more than 20 var
genes highly transcribed in the inoculum; notably, the expression hierarchy was dominated by group
B variants and there was very low (or undetectable) transcription of most virulence-associated group
A or DC8 var genes (Figure 4a and Figure 4—source data 1). One exception was PF3D7_0400400
(previously PFD0020c), which encodes a group A brain endothelial cell binding PfEMP1 variant
(Claessens et al., 2012). We further found that group B var genes dominated the PfEMP1 landscape
when parasites were isolated from our mosquito challenge cohort, albeit with a higher proportion of
var gene reads mapping to group A and with two DC8-like variants highly transcribed in some volun-
teers (PF3D7_0600200 (aka PFF0010w) and PF3D7_0800300 (aka PF08_0140)) (Figure 4a, Figure 4—
figure supplement 1a–b and Figure 4—source data 1). Our data therefore confirmed previous
observations that whilst malaria parasites exit the human liver expressing a diverse var gene reper-
toire, variants associated with severe disease constitute a minority population (Bachmann et al.,
2019; Bachmann et al., 2016; Peters et al., 2002; Wang et al., 2009).
Current theory predicts that group A and DC8 variants should rapidly and preferentially expand
in naive hosts because of an intrinsic growth and/or survival advantage favouring their selection
(Abdi et al., 2017; Bull et al., 2000; Jensen et al., 2004). Blood challenge provides a unique oppor-
tunity to directly test this hypothesis as it increases the number of asexual replication cycles over
which variant switching and selection can take place (cf. mosquito challenge [(Draper et al., 2018)]).
Parasites were therefore isolated from volunteers infected by blood challenge and processed imme-
diately (without culture) for RNA-sequencing; after six cycles of replication, the expression hierarchy
of var genes was essentially unchanged from that observed in the inoculum (Figure 4a and Fig-
ure 4—figure supplement 1b). Indeed, the group B var gene PF3D7_1041300 remained the most
highly expressed variant in every volunteer, and transcription of group A and DC8 var genes
remained low or undetectable at diagnosis (Figure 4—source data 1). Surprisingly, this included the
virulence-associated brain endothelial cell binding variant PF3D7_0400400, which was transcribed at
the start of infection (Figure 4a). We could further highlight the significance of this result by looking
only at intron-spanning reads, which must derive from functional var gene transcripts (rather than
regulatory antisense transcripts, Amit-Avraham et al., 2015). We found that PF3D7_0400400 was
functionally transcribed in the inoculum but intron-spanning reads were absent in all volunteer sam-
ples (Figure 4—figure supplement 1c). Differential gene expression analysis (using DESeq2) then
confirmed that no var gene was more highly transcribed at the end of infection as compared to the
start (adj p<0.01). Evidently, there was no preferential expansion of group A or DC8 variants within
the time-frame of this study.
Figure 3 continued
baseline (day  1). One dot represents one volunteer (no data for v020) and dots are colour-coded by host response. The green line represents the
best-fit model (p value of the slope is shown) and dashed lines are the 95% confidence intervals. (E) Log10 transformed intensity values of adenosine in
plasma during infection. An authentic standard was run in tandem with all samples to validate adenosine detection. (F) Range-scaled intensity values of
10 plasma metabolites that were differentially abundant during infection. Metabolites (rows) and samples (columns) are ordered by hierarchical
clustering. Note that an authentic standard was used to validate detection of all underlined metabolites and the full name for oxoglutaric acid is 4-
hydroxy-2-oxoglutaric acid. (E and F) Only plasma samples from the most inflammatory and symptomatic volunteers (v016, v017, and v013), the
suppressor volunteers (v022 and v019) and two unresponsive volunteers (v018 and v208) were analysed for metabolite abundance.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Adverse events after blood challenge.
Figure supplement 2. Inflammation is linked to hallmark symptoms of malaria.
Figure supplement 3. A conserved early metabolic signature of falciparum malaria.
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Figure 4. Parasite variants associated with severe disease do not rapidly expand in naive hosts. (A and B) Rlog expression values of var (A) and rifin (B)
genes in the inoculum and diagnosis parasite samples after blood challenge (blue study); parasites obtained from volunteers infected by mosquito bite
are also shown (pink study). Genes (rows) are ordered by hierarchical clustering and colour-coded by var type; parasite samples are colour-coded by
host response; and in vitro cultured ring-stage parasites are shown for comparison. Two volunteers did not have parasite sequencing data
Figure 4 continued on next page
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When we expanded our analysis to include rifin genes we still could find no evidence of gene
switching or selection. Indeed, the only rifin that was differentially expressed at diagnosis
(PF3D7_0401600, log2 fold-change = 7.59, adj p=0.0002) was already dominantly transcribed at the
start of infection (Figure 4b). It should be noted, however, that ex vivo RNA-sequencing (ideal for
var gene analysis as whole blood contains mainly ring-stage parasites) is less suited to rifins, which
are predominantly transcribed at later stages of the parasite life cycle (Kyes et al., 2000). We there-
fore moved on to directly test the relationship between inflammation and parasite VSA expression.
Once again, we used DESeq2 to identify differentially expressed parasite genes but this time
between inflammatory volunteers and the rest of the cohort. There were no differentially expressed
var or rifin genes (adj p<0.01). In fact, only one differentially expressed gene could be identified
(Pfck1) - this gene encodes casein kinase one and was more highly transcribed in the inflammatory
group (PF3D7_1136500, log2 fold-change = 7.32, adj p=0.002). The diverse clinical outcomes
observed in this trial cannot therefore be easily explained by variation in parasite gene expression;
instead, they must largely originate from host-intrinsic immune variation.
Discussion
In this study, we set out to map immune variation in falciparum malaria and explore the interplay
between parasite and host factors in shaping outcome of infection. Of particular interest was how
group A and DC8 var genes, which are associated with severe malaria in children and adults, come
to dominate infections when parasites egress from the liver expressing mainly group B and C var
genes. One leading hypothesis is that group A/DC8 variants have an intrinsic growth and/or survival
advantage leading to their rapid expansion in naive hosts. To directly test this hypothesis, we devel-
oped methodology that allowed us to measure var gene expression across 10 days of infection in a
human blood challenge model. Surprisingly, we found no transcriptional evidence for the preferen-
tial expansion of group A or DC8 variants. These data indicate that other factors (such as inflamma-
tion, tissue damage, or endothelium activation) must be required to promote the selection of these
variants in hosts that develop severe disease. We also found that the diverse outcomes of controlled
human malaria infection must largely originate from host-intrinsic variation as just one differentially
expressed parasite gene could be identified between volunteers that trigger systemic inflammation
(leading to hallmark symptoms of clinical malaria) and those that remain asymptomatic (by prevent-
ing or delaying the acute phase response). Taken together, these data emphasise the importance of
the human host in determining their own fate.
This conclusion is well supported by epidemiological studies showing that the clinical manifesta-
tions of severe malaria depend upon host age (Dondorp et al., 2008) and children learn to tolerate
high parasite densities, which could otherwise cause life-threatening disease (Gonçalves et al.,
2014; Ademolue et al., 2017). As such, we must understand the rules of immune decision-making if
we want to uncouple mechanisms of pathology versus tolerance. In this study, we identified at least
three possible early outcomes of blood-stage infection. The most likely outcome is interferon-stimu-
lated inflammation, which is characterised by activation of myeloid cells and systemic release of
inflammatory molecules. Notably, only inflammatory volunteers developed hallmark signs and symp-
toms of malaria (e.g. pyrexia and lymphopenia) providing further support for the idea that inflamma-
tion causes the earliest manifestations of disease. It is often assumed that the flip-side to this cost is
Figure 4 continued
(unresponsive volunteer v208 and suppressor volunteer v022) and the two inoculum samples are technical replicates of one biological sample. The var
(PF3D7_1041300) and rifin (PF3D7_0401600) genes dominantly expressed across all samples are labelled. Var genes associated with severe disease
(group A variant PF3D7_0400400 and DC8-like variants PF3D7_0600200 and PF3D7_0800300) are also labelled. Gene counts show the number of
parasite genes that have at least three uniquely mapping reads; this provides a measure of genome coverage in every sample.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Rlog expression values of var and rifin genes in parasites isolated from whole blood after controlled human malaria infection.
Figure supplement 1. Group B var genes dominate the PfEMP1 landscape in naive hosts.
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immediate or early control of parasite burden and yet we find that the parasite multiplication rate of
the inflammatory group is comparable to all other volunteers. It therefore appears that we might
need to re-assess the role of innate immunity in the first hours and days of the pathogenic blood
cycle – rather than serving as an early brake on parasite replication it may be that systemic inflamma-
tion primarily functions to switch bone marrow production in favour of myelopoiesis and mobilise
the required effector cells to the spleen.
Recent evidence suggests that blood-stage parasites first trigger interferon signalling in the bone
marrow (Spaulding et al., 2016) and the transcriptional changes we observe in whole blood are thus
likely to be a signature of activated monocytes and neutrophils trafficking from bone marrow to
spleen. Furthermore, the major secreted products of this emergency myeloid response (CXCL9 and
CXCL10) specifically recruit T cells out of the circulation (Groom and Luster, 2011). The innate
response to malaria therefore quickly re-structures and co-localises key strands of the immune sys-
tem; whether this leads to an effective response that can limit parasite burden and minimise collat-
eral damage will depend upon the outcome of cell-cell circuits in the spleen. Measuring the
activation and differentiation of CD4+ T cells – the key orchestrators of innate and adaptive immunity
– would provide a downstream readout of these critical tissue-specific interactions in human volun-
teers. Unfortunately, we cannot begin to examine these outcomes in our current datasets because at
our final time-point (diagnosis) CD4+ T cells are still sequestered in the tissue. Nevertheless, future
studies could extend sampling beyond drug treatment to analyse resolution of the acute phase
response and examine the heterogeneity between volunteers in T cell profiles as they are released
back into the circulation. Due to the inherent adaptive plasticity of human T cells (Sallusto et al.,
2018), this is likely to reveal much greater variation between hosts in their response to a first malaria
episode.
A second common outcome of infection in this study was immune quiescence. Although the
course of infection tended to be shorter in unresponsive volunteers than the others this could not
fully explain their lack of response to blood challenge. After all, half of unresponsive volunteers (2/4)
had parasite densities comparable to half of the inflammatory group (4/8). And furthermore, v017
triggered a measurable inflammatory response at just 157 parasites ml 1, whereas v018 remained
unresponsive at 20,000 parasites ml 1. These observations are entirely in-line with meta-analysis of
historical malariotherapy data that measured the pyrogenic threshold in falciparum malaria as span-
ning more than four-orders of magnitude (Molineaux et al., 2002). Immune variation therefore dic-
tates how you respond and when. Pushing up the pyrogenic threshold to disarm emergency
myelopoiesis is a well-recognised host adaptation that promotes immune quiescence and allows
individuals to transition from clinical to asymptomatic malaria (usually in adolescence, Gatton and
Cheng, 2002; Portugal et al., 2014). This is helpful if you have developed partial humoral immunity
that can restrict total pathogen load but whether a pre-existing high threshold is advantageous in a
naive host is unclear. This could indicate a natural tendency towards disease tolerance
(Medzhitov et al., 2012) or it may simply delay the time until an emergency myeloid response inevi-
tably has to be triggered. Indeed, it remains a possibility that all naive hosts (including those that ini-
tially suppress genes involved in myeloid cell activation) will eventually converge on interferon-
stimulated inflammation as the infection progresses. After all, every volunteer increased their circu-
lating levels of adenosine as part of a shared metabolic response to blood-stage infection and aden-
osine is a potent paracrine inhibitor of inflammation (Faas et al., 2017). This metabolic switch may
therefore represent a hardwired mechanism of self-regulation because systemic inflammation is an
unavoidable fate in naive hosts.
We also examined the in vivo relationship between inflammation and parasite VSA expression,
asking whether this could shape the clinical outcome of controlled human malaria infection. We con-
firmed the previous finding that group B var genes, which encode PfEMP1 variants associated with
uncomplicated malaria, are dominantly expressed in human volunteers infected by mosquito bite
(Bachmann et al., 2019; Bachmann et al., 2016; Peters et al., 2002; Wang et al., 2009). The
unique features of the blood challenge model then allowed us to examine the widely held belief that
variants associated with severe disease rapidly and preferentially expand in naive hosts. Unexpect-
edly, we found no evidence to support this hypothesis. In fact, we found limited transcriptional evi-
dence of var gene switching or selection over six cycles of replication. This is in contrast to a
previous study that suggested var gene expression changes within the first few days of blood-stage
infection (Lavstsen et al., 2005). However, in that study parasites were isolated from volunteers and
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then placed into culture for one month before var gene profiling – switching may therefore have
occurred in vitro confounding interpretation of these data. Our study, which measured var gene
expression ex vivo, avoids any bias introduced by culturing parasites but nevertheless has limitations
that require careful consideration. In particular, we have studied a single parasite genotype in a small
number of hosts over a short window of infection. The potential for these factors to explain the
absence of var gene switching/selection are considered below.
This study (and most previous CHMI trials) used the 3D7 P. falciparum clone or its parent line
NF54 (Stanisic et al., 2018). The 3D7 clone was cultured for many years before preparation of the
inoculum used for blood challenge (Cheng et al., 1997) and could have acquired mutations that
affect its behaviour in vivo (Claessens et al., 2017). This could theoretically include a reduced capac-
ity to switch var gene expression; direct experimental evidence that the 3D7 parasites used in this
study have retained their ability to switch would therefore strengthen our conclusions. Nevertheless,
in the absence of these data it is notable that a previous study using the same 3D7 inoculum clearly
showed var gene switching when parasites recovered from volunteers were returned to culture
(Peters et al., 2002). Furthermore, in our mosquito challenge cohort there was considerable varia-
tion between volunteers in which group A and DC8 var genes were highly transcribed, indicating
that 3D7 has retained its potential to express a wide range of virulence-associated variants. Overall,
we consider it possible, but unlikely, that our data can be explained by a mutation in 3D7 that affects
var gene switching. A more interesting possibility is that parasite genotypes may vary in their capac-
ity to switch towards group A or DC8 variants. Additional parasite genotypes are being developed
for CHMI that would allow this hypothesis to be tested in vivo (Moser et al., 2020; Stanisic et al.,
2015).
Another possibility is that 3D7 might only switch towards group A/DC8 variants in a minority of
hosts. Indeed, in endemic settings the frequency of severe disease is low (around 1% of all clinical
episodes) and the small number of volunteers in this study would be unlikely to capture a rare event.
Nevertheless, it is clear that the incidence of severe malaria is much higher in naive hosts
(Marsh and Snow, 1997). And moreover, naive hosts in endemic areas are generally infants and
young children who are much less susceptible to severe disease than naive adults (Baird et al.,
2003; Baird et al., 1998). In CHMI, we are therefore recruiting those individuals who are most likely
to develop life-threatening complications in the absence of drug treatment; we can therefore rea-
sonably expect that severe disease would not have been a rare outcome of infection in our two
cohorts of volunteers. As such, it is unlikely that a different pattern of var gene switching would have
been observed if a larger number of volunteers were examined, but this cannot be excluded. An
alternative explanation is that a parasite density threshold needs to be crossed to promote var gene
switching in vivo, and this threshold is not reached in controlled human malaria infection. In support
of this argument, parasite density is known to be an important factor in severe malaria
(Dondorp et al., 2005) and this effect could potentially be mediated by quorum sensing, which
operates in trypanasomes to control their virulence (Rojas et al., 2019). However, no external signals
that can cause var gene switching have yet been identified (Deitsch and Dzikowski, 2017;
Guizetti and Scherf, 2013).
How then do group A and DC8 var genes become predominantly transcribed in patients with
severe malaria? The most plausible explanation for our data is that the short duration of CHMI does
not allow enough time for the selection of these variants, and that this would have been observed if
drug treatment was withheld. However, the preferential expansion of group A/DC8 variants would
need to occur rapidly because at the mean parasite multiplication rate of 10 seen in this study only
2–3 more cycles of replication would have been required for some volunteers to reach parasite bur-
dens at which severe disease can occur (5000 parasites ml 1 or 0.1% parasitaemia [Field, 1949]). Var
gene switching rates of culture-adapted parasites are low in vitro (estimated mean on-rates of
0.025–3% per generation [Horrocks et al., 2004; Roberts et al., 1992; Ye et al., 2015]) and
although mathematical modelling suggests the possibility of higher switching rates in vivo
(Gatton et al., 2003) experimental data are lacking. We therefore propose that rather than a sudden
increase in the rate of switching an environmental change instead leads to the rapid selection of var-
iants associated with severe disease – this could include systemic inflammation, collateral tissue dam-
age, metabolic disturbance and/or endothelium activation. In this scenario, group A and DC8
variants have no intrinsic growth or survival advantage; instead, their preferential expansion in naive
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hosts relies upon infection-induced changes in their within-host environment. The responsibility for
severe malaria is therefore likely shared between parasite and host.
In theory, inflammation will lead to the selection of parasites expressing group A and DC8 var
genes because of cytokine-mediated upregulation of endothelial receptors such as ICAM-1, which is
upregulated in response to TNF (Bernabeu et al., 2019). This is predicted to enhance their cytoad-
herence and reduce mechanical clearance in the spleen, as compared to parasites expressing group
B and C var genes that bind only CD36 (Smith et al., 2013). In our study, there was no evidence for
increased transcription of group A or DC8 var genes in volunteers who showed clear clinical, tran-
scriptional, and biochemical evidence of inflammation. However, circulating levels of plasma TNF
had not yet increased at diagnosis and so more time is clearly required for interferon signalling to
drive the cytokine cascades necessary to activate endothelial cells. One argument against an essen-
tial role for inflammation is that Endothelial Protein C Receptor (EPCR), currently thought to be a
key receptor for cytoadherence in cerebral malaria (Turner et al., 2013), is downregulated on micro-
vascular endothelial cells exposed to inflammatory cytokines (Bernabeu et al., 2019). The role of
EPCR as a receptor for infected red cell binding remains controversial (Azasi et al., 2018) but if
EPCR does prove to be a major host receptor for sequestration then selection of dual-binders that
also interact with ICAM-1 (Lennartz et al., 2017) would be expected in an inflammatory environ-
ment. One other intriguing finding that emerged from our analysis was that parasites from inflamma-
tory volunteers express higher levels of Pfck1 – a serine-threonine kinase (Cheong and Virshup,
2011; Jiang et al., 2018) that has been shown to regulate pathogen virulence in leishmaniasis (Dan-
Goor et al., 2013) and toxoplasmosis (Wang et al., 2016), and which may be able to directly regu-
late type I interferon signalling (Liu et al., 2009). If this observation could be validated in a separate
study it would identify a possible mechanism through which malaria parasites may in turn attempt to
influence the host response to infection. CHMI trials that follow volunteers for one or two more
blood cycles would be required to explore the consequences of increased Pfck1 transcription and of
prolonged systemic inflammation, and consideration should be given as to whether this can be done
safely.
To complement the study of var gene switching and selection in naive hosts, future work should
also aim to examine the neutralisation of parasite variants associated with severe disease in semi-
immune adults. Immunity to severe malaria can be acquired early in life (Gonçalves et al., 2014) and
so will require the rapid production of cross-reactive antibodies that recognise and eliminate group
A and DC8 variants if these are sufficient to cause life-threatening disease. Whether antibodies can
effectively neutralise these variants in vivo remains to be directly shown, but the RNA-sequencing
methodology that we developed for this study (https://doi.org/10.17504/protocols.io.brgjm3un)
now allows transcriptional profiling of P. falciparum at ultra-low densities – indeed, we can spike just
2000 ring-stage parasites into 50 ml whole blood and map their complete VSA profiles (Figure 4).
Applying this methodology to CHMI in an endemic setting would therefore allow switching and
selection to be tracked under immune pressure in volunteers that can restrict and slow parasite
replication.
In summary, our study failed to provide compelling transcriptional evidence that parasite variants
associated with severe disease rapidly and preferentially expand in vivo. Our data do not therefore
support the hypothesis that group A and DC8 variants have an intrinsic growth and/or survival
advantage in naive hosts. This leaves open the question as to how these variants come to dominate
severe episodes of malaria when parasites egress from the liver expressing mainly group B and C var
genes. We propose that infection-induced changes in the host environment (including inflammation)
can rapidly select for parasites with a higher efficiency to cytoadhere, sequester and cause severe
disease. Notably, our study uncovered marked variation between volunteers in their innate response
to blood-stage parasites, which might explain why not all clinical episodes lead to severe malaria. An
enormous body of evidence now supports the critical role of host-intrinsic variation in shaping the
human immune response to pathogens and their products (Bakker et al., 2018; Brodin et al., 2015;
Li et al., 2016; Patin et al., 2018; Piasecka et al., 2018; Ter Horst et al., 2016); remarkably most
of this variation is underpinned by non-heritable factors (Bakker et al., 2018; Brodin et al., 2015;
Piasecka et al., 2018; Ter Horst et al., 2016). Taken together, these data emphasise the impor-
tance of the human host in shaping their own fate.
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Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Strain, strain
background (Plasmodium falciparum)
clone 3D7 Cheng et al., 1997 PMID:9347970
Sequence-
based reagent
TaqMan probe Applied Biosystems 50 FAM
AACAATTGGAGGGCAAG
NFQ-MGB 30
Sequence-
based reagent
ISPCR primer biomers.net 5’- AAG
CAGTGGTATCAACGCAG
AGT  3’
Sequence-
based reagent
LNA-modified TSO exiqon.com 5’- AAGCAGTGGTATCAACG
CAGAGTACATrGrG+G
 3’
Sequence-
based reagent
Oligo-dT30VN biomers.net 5’- AAGC
AGTGGTATCAACGCAGAGT
ACT30VN  3’
Commercial
assay or kit
Tempus spin
RNA isolation
Applied
Biosystems
cat. no.
4378926
Commercial
assay or kit
RNA clean
and concentrator
Zymo
Research
cat. no.
R1016
Commercial
assay or kit
Globin-Zero Gold Illumina cat. no. GZG1224
Commercial
assay or kit
RNA 6000 pico chip Agilent cat. no.
5067–1513
Commercial
assay or kit
High sensitivity
DNA kit bioanalyzer
Agilent cat. no.
5067–4626
Commercial
assay or kit
TruSeq stranded
mRNA library
Illumina cat. no.
RS-122–2101
Commercial
assay or kit
NEBNext Ultra
DNA library prep kit
New England
Biolabs
cat. no.
E7370
Software,
algorithm
Kallisto v0.42.3 Bray et al., 2016 RRID:SCR_016582 PMID:27043002
Software,
algorithm
EdgeR Robinson et al., 2010 RRID:SCR_012802 PMID:19910308
Software,
algorithm
ClueGO v2.5.4 Bindea et al., 2009 RRID:SCR_005748 PMID:19237447
Software,
algorithm
IDEOM Creek et al., 2012 PMID:22308147
Software,
algorithm
mzCloud RRID:SCR_014669
Software,
algorithm
DESeq2 Love et al., 2014 RRID:SCR_015687 PMID:25516281
Other Saponin from
quillaja bark
Sigma Aldrich cat. no.
S7900
test each batch
Other Leucoflex
LXT filters
Macopharma macopharma.com
/transfusion
Other KAPA HiFi
HotStart ReadyMix
Biosystems cat. no.
KK2601
Other AMPure XP beads Beckman Coulter cat. no.
A63881
Study participants and ethical approval
The 14 volunteers recruited for blood challenge were infectivity controls in a phase I/IIa vaccine trial
(VAC054) that took place at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM),
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Oxford (Payne et al., 2016). This study received ethical approval from the UK NHS Research Ethics
Service (Oxfordshire Research Ethics Committee A, 13/SC/0596) and the Western Institutional
Review Board (WIRB) in the USA (20131985). The study was approved by the UK Medicines and
Healthcare products Regulatory Agency (MHRA) (21584/0326/001–0001) and the trial was registered
on ClinicalTrials.gov (NCT02044198). The five volunteers infected by mosquito bite were recruited at
the same site and this study (VAC065) received ethical approval from the UK NHS Research Ethics
Service (South Central Berkshire Research Ethics Committee, 16/SC/0261) and was approved by the
UK MHRA (21584/0360/001–0001). The trial was registered on ClinicalTrials.gov (NCT02905019).
Both trials were conducted according to the principles of the current revision of the Declaration of
Helsinki 2008 and in full conformity with the ICH guidelines for Good Clinical Practice (GCP).
Controlled human malaria infection
Blood challenge
Details of inoculum preparation and assessment of parasite viability have been published previously
(Payne et al., 2016). The 14 volunteers (non-vaccinated infectivity controls) received an identical
challenge by intravenous injection of 690 P. falciparum (clone 3D7) infected erythrocytes in 5 ml of
0.9% saline. All inoculations were performed within 2 hr and 13 min of inoculum preparation.
Mosquito challenge
CHMI was performed as previously described (Sheehy et al., 2012) using five infectious bites from
P. falciparum (clone 3D7) infected Anopheles stephensi mosquitoes at the Alexander Fleming Build-
ing, Imperial College, London, UK. Infected mosquitoes were supplied by Jittawadee R. Murphy,
Department of Entomology, Walter Reed Army Institute of Research, Washington, DC, USA.
Monitoring volunteers
Blood samples were collected to measure parasitaemia by qPCR twice daily, starting 2 days post-
infection for blood challenge and 6.5 days post-infection for mosquito challenge. In both trials, thick
blood smears were also evaluated by experienced microscopists at each time-point. All reported
clinical symptoms (pyrexia, fever, rigor, chills, sweats, headache, myalgia, arthralgia, back pain,
fatigue, nausea, vomiting, and diarrhoea) were recorded as adverse events and assigned a severity
score: 1 - transient or mild discomfort (no medical intervention required); 2 - mild to moderate limita-
tion in activity (no or minimal medical intervention required); 3 - marked or severe limitation in activ-
ity requiring assistance (may require medical intervention). A cumulative clinical score was then
obtained by summing these adverse events across all time-points for each volunteer. At every clinic
visit, staff at the CCVTM also assessed core temperature, heart rate and blood pressure. And on
days  1, 6, 28, and 90 post-infection (plus diagnosis) full blood counts and blood biochemistry were
performed at the Churchill and John Radcliffe Hospitals in Oxford, providing five-part differential
white cell counts and a quantitative assessment of electrolytes, urea, creatinine, bilirubin, alanine
aminotransferase, alkaline phosphatase and albumin.
Diagnostic criteria and drug treatment
Treatment with the artemether and lumefantrine combination drug Riamet was prescribed to volun-
teers when two out of three diagnostic criteria were met: a positive thick blood smear and/or para-
site density >500 parasites ml 1 by qPCR and/or symptoms consistent with malaria.
qPCR and parasite multiplication rate modelling
Blood was collected and prepared for qPCR analysis as previously described (Payne et al., 2016;
Sheehy et al., 2012). In brief, DNA was extracted from 0.5 ml whole blood using the Qiagen Blood
Mini Kit (as per manufacturer’s instructions) and 10% of each extraction was run in triplicate wells
(equating to 150 ml total blood volume). Previously published primers with TaqMan probes (50 FAM-
AAC AAT TGG AGG GCA AGNFQ-MGB 30) (Applied Biosystems) were used to amplify the P. falci-
parum 18S ribosomal region and parasites ml 1 equivalent mean values were calculated using a
defined plasmid standard curve and TaqMan absolute quantitation. Mean values below 20 parasites
ml 1 (or values with only one positive replicate of the three tested) were classed as negative. Para-
site multiplication rate (PMR) was then calculated using a linear model fitted to log10 transformed
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qPCR data, as previously described (Sheehy et al., 2012; Douglas et al., 2013). In the blood chal-
lenge model, fitted lines were constrained to pass through the known starting parasitemia, deter-
mined by the viability of the inoculum and a weight-based estimate of each volunteer’s total blood
volume (Payne et al., 2016).
Uninfected control volunteers
Blood challenge
Four healthy adult volunteers were recruited at the University of Edinburgh to serve as uninfected
controls for the blood challenge study. These volunteers had no history of malaria, and included two
male and two female Caucasians with a mean age of 24 years (range 22–25). Written informed con-
sent was given by all participants and the study was approved by the University of Edinburgh, School
of Biological Sciences Ethical Review Committee (arowe-0002 and pspence-0002).
Mosquito challenge
One volunteer recruited to the VAC065 study was exposed to the bites of 5 infectious mosquitoes
but did not develop measurable parasitaemia at any point during the 28 day study (limit of detection
is five parasites ml 1). This volunteer therefore served as an internal uninfected control for the mos-
quito challenge study.
Processing whole blood for host RNA and plasma
Blood challenge
For microarray analysis, 3 ml venous blood was drawn directly into a Tempus Blood RNA Tube
(Applied Biosystems), mixed and stored at  80˚C. To obtain plasma, 14 ml venous blood was drawn
into lithium heparin vacutainers, transferred to Leucosep tubes (Greiner Bio-One) containing 15 ml
Lymphoprep (Axis Shield) and centrifuged at 1000xg for 13 min at room temperature. Two ml of the
plasma fraction was collected, snap-frozen on dry ice and stored at  80˚C.
Mosquito challenge
For host RNA-sequencing, 6 ml venous blood was drawn into EDTA-coated vacutainers, from which
1 ml blood was removed and mixed with 2 ml Tempus reagent; samples were stored at  80˚C. To
obtain platelet-depleted plasma, a further 1 ml blood was removed from the vacutainer and given
two spins; first at 1000xg for 10 min and then at 2000xg for 15 min (both at 4˚C). After each spin,
the plasma was transferred to a new tube (leaving behind any residual red cells or pelleted platelets)
and finally the plasma was snap-frozen on dry ice and stored at  80˚C.
Host RNA extraction, quantification, and quality control
RNA extraction was performed with the Tempus Spin RNA Isolation Kit (Applied Biosystems) accord-
ing to the manufacturer’s instructions. The following modification was applied to mosquito challenge
samples because of their reduced volume: after thawing, just 1 ml PBS was added to each sample to
maintain Tempus stabilising reagent at the correct final concentration. Note that for all samples, a
DNase treatment step using Absolute RNA wash solution (Applied Biosystems) was included for the
removal of genomic DNA. Samples were quantified by nanodrop and RNA integrity was assessed on
an Agilent 2100 Bioanalyzer using RNA 6000 nano chips. A RIN value above 7.0 was accepted as suf-
ficiently high-quality RNA for downstream steps.
Host microarray and data processing (blood challenge)
Whole blood transcriptomics was undertaken with the Affymetrix GeneChip Human Transcriptome
Array 2.0 ST by Hologic Ltd. (Manchester, UK); samples were randomised to ensure unbiased sam-
ple-chip positioning. Raw array data in the form of compressed CEL files were processed in the R
environment using Bioconductor packages (oligo, pd.hta.2.0, affy) to generate an HTAFeatureSet
object (gene level). After visual inspection for QC purposes, raw and normalised (using the rma()
function of the affy package or normalizeQuantiles() function from the limma Bioconductor package,
as appropriate) versions of the intensities were retained for subsequent analyses. Array feature anno-
tation was generated using the AnnotationForge package and the Bioconductor human reference
database (org.Hs.eg.db).
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Plotting the 100 protein-coding genes with highest variance
For each volunteer, a subset of the data was made encompassing all available time-points in chrono-
logical order. For each array feature, the variance of the intensities across the time-points was calcu-
lated using the var() function in R. The 100 protein-coding array features with the highest variance
were then selected and for each of these features the median value of the intensities across all time-
points was calculated and subtracted from the actual intensity values, resulting in a set of ‘deviation
from median’ values. These values were plotted using the heatmap.2() function in R and dendro-
grams, where shown, were calculated based on Euclidean distance measures of the input data
(hclust() and dist() functions of the stats package).
Plotting the 517-gene superset
The lists of 100 protein-coding genes with highest variance in each of the 14 volunteers infected by
blood challenge were merged to create a non-redundant set of 517 unique genes. Log2 transformed
intensity values were then scaled with scale (scale=TRUE, center=TRUE), plotted with pheatmap and
clustered using hclust and cutree in R, with k = 8.
PCA plots of the 517-gene superset
For each volunteer, a subset of the data was made encompassing all available time-points in chrono-
logical order. The log2 transformed intensity values of the 517 genes were normalised using the nor-
malizeQuantiles()function from the limma Bioconductor package prior to principal component
analysis using the prcomp() function of the stats Bioconductor package. Plots of the first two dimen-
sions were generated using the standard plot() function of the graphics package. To measure the
magnitude of each volunteer’s immune response we calculated the Euclidean distance travelled
along principal component 1, as this accounted for almost all of the variance in every time-course.
As every sample in a time-course was centred around zero we calculated the distance travelled for
every volunteer (relative to their own average position through time) as the x-coordinate of the diag-
nosis sample.
Differential gene expression
Analysis of differential gene expression was carried out using the limma package from Bioconductor,
with eBayes correction for multiple testing; an adjusted p value below 0.05 was required for signifi-
cance. This analysis was performed to quantify the number of differentially expressed genes
between time-points for each group (unresponsive, inflammatory, and suppressor). It was also car-
ried out to quantify the number of differentially expressed genes between groups at a given time-
point.
Allocation of volunteers to groups after blood challenge
To be classified as responsive to blood challenge volunteers had to pass two sequential thresholds:
first, for every volunteer the mean variance of their 50 most variable protein-coding genes was calcu-
lated. This figure had to be at least 1.5-fold higher than the mean of the four uninfected controls
(i.e. 1.5  0.202 = 0.303). Second, the distance travelled in each volunteer’s PCA plot of the 517-
gene superset had to be greater than two standard deviations above the mean of the four unin-
fected controls (i.e. 2.67 + (2  1.102)=4.874). Volunteers had to pass both thresholds in order to
be classified as responsive; those who failed one or both of these tests (v018, v012, v208, and v020)
were classified as unresponsive. The remaining volunteers were then grouped into inflammatory
(v016, v017, v013, v027, v026, v206, v106, and v024) or suppressor (v022 and v019) hosts based on
their upregulation of clusters 2 and 4 or downregulation of clusters 1 and 3, respectively (see Fig-
ure 1). Note that differential gene expression analysis (as detailed above) was used to confirm that
the unresponsive group had zero differentially expressed genes at diagnosis (compared to baseline).
Host RNA-sequencing and data processing (mosquito challenge)
Indexed sequencing libraries were prepared from 500 ng RNA using the TruSeq Stranded mRNA
Library kit (Illumina), according to the manufacturer’s instructions. Samples were pooled and
sequenced on two separate lanes of the same Illumina HiSeq v4 flow cell to generate ~33 million
reads per sample (75 bp paired-end reads). Note that globin depletion was not performed; instead,
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sequencing was carried out to sufficient depth that the globin reads (accounting for no more than
20% of any given sample) could simply be discarded during data processing. Read counts per gene
were quantified against the Gencode human v28 basic transcript sequences (Frankish et al., 2019)
using Kallisto v0.42.3 (92). The index was built using default parameters and quantification was per-
formed with -t 12 -b 0; genes not expressed with at least one count per million in at least one sam-
ple were excluded. EdgeR (Robinson et al., 2010) was used to identify highly dispersed genes
(BCV >0.4 and FDR < 0.1) for each volunteer’s time-course with the exact test. Next, the lists of
highly dispersed genes in each of the five volunteers infected by mosquito bite were merged to cre-
ate a non-redundant set of 226 unique genes, which were used for clustering with hclust in the
pheatmap R package. This identified a single major cluster comprising 117 unique genes that was
taken forward for downstream analyses (e.g. plotting the 117-gene superset and ClueGO). Note
that to visualise and cluster the 226 unique genes and the 117-gene superset, read counts across
the entire dataset were normalised using rlogs (blind=TRUE) in DESeq2 (Love et al., 2014).
Gene ontology analysis and networks (ClueGO)
Blood challenge
The list of 2028 genes differentially expressed at diagnosis in the inflammatory group was imported
into ClueGO v2.5.4 (Bindea et al., 2009; Mlecnik et al., 2014). ClueGO identified the significantly
enriched GO terms associated with these genes and placed them into a functionally organised non-
redundant gene ontology network based on the following parameters: pvalue cutoff = 0.05; correc-
tion method used = Bonferroni step down; min. GO level = 5; max. GO level = 11; number of
genes = 3; min. percentage = 5.0; GO fusion = true; sharing group percentage = 40.0; merge redun-
dant groups with >40.0% overlap; kappa score threshold = 0.4; and evidence codes used [All]. Each
of the 34 functional groups was assigned a unique colour and a network was then generated using
an edge-weighted spring-embedded layout based on kappa score. To provide an overview of the
inflammatory response we then labelled the leading GO term in the top 12 functional groups, as fol-
lows: groups were first ordered by adj p value; starting with the most significant group we chose the
level 4 GO term with the highest significance and made this the group name; we then moved on to
the next most significant group and again chose the level 4 GO term with the highest significance as
group name; we repeated this process until 12 groups had been named. Note that there were two
exceptions to these rules: first, if there was not a level 4 GO term within a group then this group was
excluded (to avoid naming groups that were too broad or specific in ascribing function); and second,
if the most significant level 4 GO term was shared with a group already named then this GO term
was excluded and the group was instead named after the next most significant level 4 GO term (to
avoid redundancy).
Mosquito challenge
The 117-gene superset was imported into ClueGO to identify the significant GO terms associated
with these genes. This was carried out exactly as described for blood challenge with the exception
of the following parameter changes: number of genes = 2; min. percentage = 4.0; merge redundant
groups with >50.0% overlap.
Quantification of cytokines and chemokines in plasma
Interferon alpha (IFNa), interferon gamma (IFNg), CXCL9 (MIG), and CXCL10 (IP-10) were quantified
in plasma as part of a custom-design multiplex assay from BioLegend (LegendPlex). Samples were
run in duplicate and the assay was performed according to the manufacturer’s instructions using low
protein-binding filter-bottom plates (Merck). Beads were acquired on a BD LSRFortessa running
FACSDiva software and data were analysed with LEGENDPlex analysis software. For blood chal-
lenge, data are presented as fold-change relative to pre-infection samples; when analytes were
undetectable samples were simply assigned the largest integer below the limit of detection to allow
normalisation and graphing of all time-points.
Quantification of Angiopoietin-2 in plasma
Angiopoietin-2 was measured in plasma at pre-infection and diagnosis time-points using the Human
Angiopoietin-2 Quantikine ELISA kit from R and D Systems. Samples were run in duplicate and the
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assay performed as per the manufacturer’s instructions. Optical density (OD) was determined on a
Multiskan Ascent plate reader by subtracting measurements taken at 570 nm wavelength from read-
ings at 450 nm. All samples and standards were background-corrected by subtracting the mean OD
measured in blank wells containing only assay diluent. A seven-point standard curve was then con-
structed by plotting the mean absorbance of each standard against known concentration and using
regression analysis to draw a best fit line (R2 = 0.998). Data are presented as mean concentration of
the duplicate samples.
Detection of anti-Cytomegalovirus IgG in plasma
Cytomegalovirus (CMV) seropositivity was assessed in all volunteers before CHMI using an anti-CMV
IgG Human ELISA Kit (Abcam). Samples were run in duplicate and OD was determined on a Multis-
kan Ascent plate reader by subtracting measurements taken at 620 nm wavelength from readings at
450 nm. All samples and controls were background-corrected by subtracting the mean OD mea-
sured in substrate blank wells. Samples were scored positive if their absorbance value was > 10%
above the mean absorbance value of the CMV IgG cut-off control. This was calculated by converting
OD values to Standard Units using the following equation: mean sample absorbance value x 10 /
mean absorbance value of the cut-off control. Samples with < 9 standard units were classified as
CMV-negative, whereas samples with > 11 standard units were classified as CMV-positive.
LC-MS-based analysis of plasma metabolites
Malaria-induced changes in metabolite abundance were measured in seven volunteers from the
blood challenge cohort: two unresponsive volunteers (v018 and v208), the three most inflammatory
volunteers (based on upregulation of plasma CXCL10 and IFNg) (v016, v017, and v013) and the two
suppressor volunteers (v022 and v019). Samples were prepared by diluting 25 ml of plasma in 1000
ml of 4˚C (HPLC-grade) chloroform/methanol/water at a 1:2:1 ratio. Samples were then vortexed for
5 min and spun at 13,000xg for 3 min at 4˚C. After centrifugation, the supernatant was collected and
stored in cryovials at  80˚C ready for downstream processing. LC-MS-based metabolomics analyses
were conducted at Glasgow Polyomics. Hydrophilic interaction liquid chromatography (HILIC) was
performed on a Dionex UltiMate 3000 RSLC system (Thermo Fisher Scientific, UK) using a ZIC-pHILIC
column (150 mm  4.6 mm, 5 mm column from Merck Sequant). For each sample, a 10 ml volume
was injected into the system. Samples were maintained at 5˚C prior to injection. The column was
kept at 30˚C throughout the analysis and samples were eluted with a linear gradient (from 20% 20
mM ammonium carbonate in water (A) and 80% acetonitrile (B) to 80% A and 20% B) at a flowrate
of 300 ml/min over 24 min. Mass spectrometry analysis was performed on a Thermo Orbitrap QExac-
tive operated in polarity-switching ionisation mode with the following parameters: resolution of
70,000; automated gain control of 106; m/z range of 70–1,050; sheath gas flowrate of 40 arbitrary
units (au); auxiliary gas flowrate of 5 au; sweep gas flowrate of 1 au; probe temperature of 150˚C
and capillary temperature of 320˚C. The parameters for positive mode ionisation were as follows:
source voltage +3.8 kV, S-Lens RF Level 30.00, S-Lens Voltage  25.00 V, Skimmer Voltage  15.00
V, Inject Flatapole Offset  8.00 V, Bent Flatapole DC  6.00 V. For negative mode ionisation, a
source voltage of  3.8 kV was used. Volunteer samples were run alongside three mixes of authentic
standards (total number: 248) involved in various metabolic pathways to facilitate metabolite identifi-
cation based on exact mass and retention time. Fragmentation of the top 20 ions was performed
with the following parameters: collision energy: 25%; isolation window: 1.2; dynamic exclusion after
one time; exclusion duration: 6s; exclude isotopes: true; and minimum intensity: 5000. LC-MS raw
data were processed with IDEOM (using default parameters [Creek et al., 2012]), which uses the
XCMS (Smith et al., 2006) and mzMatch (Scheltema et al., 2011) software in the R environment.
The levels of reliability of the spectral assignment to metabolites, as defined by the Metabolomics
Standard Initiative (Sumner et al., 2007), are as follows: ’MSI:1 (identified metabolites)’ – high-reso-
lution mass (three ppm) and retention time (5%) matched to an authentic standard and ’MSI:2 (puta-
tively annotated compounds)’ – high-resolution mass matched to a public library (three ppm).
Xcalibur software (Thermo Fisher Scientific) was used to generate fragmentation spectra, which were
further exported into mzCloud to search for compounds in the database with matching spectra.
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Metabolomics data processing and analysis
Metabolite intensities were log2 transformed and intensity ratios were calculated as the fold-change
in metabolite abundance at day 8 or diagnosis relative to pre-infection. A pairwise comparison (t-
test) between post- and pre-infection samples was then carried out for every metabolite and p val-
ues were adjusted for multiple testing by applying a false discovery rate (FDR). Differentially abun-
dant metabolites were called using an FDR threshold of 0.1 and an intensity ratio equivalent to a
1.5-fold change in abundance. A volcano plot showing the intensity ratios and FDR-corrected p val-
ues of all metabolites was generated using ggplot2. Next, the differentially abundant metabolites
were range-scaled according to van den Berg et al., 2006 and a heatmap of range-scaled intensity
values was generated using the gplots R package. Here range-scaling is used to make every metabo-
lite equally important by scaling the intensity of each metabolite relative to its own biological range
across all samples.
Isolation of parasites for ex vivo RNA-sequencing
A step-by-step guide to our ultra-low density RNA-sequencing methodology for human malaria par-
asites is available at protocols.io (dx.doi.org/10.17504/protocols.io.brgjm3un).
Blood challenge
50 ml whole blood was drawn into lithium heparin vacutainers at diagnosis (immediately before drug
treatment) and white cells were removed by passing the blood through a leucoflex LXT filter (Maco-
pharma). The flow-through was collected into a 250 ml centrifuge bottle (with silicone O-ring) and
the filter was washed with 200 ml PBS to maximise recovery of infected red cells. The flow-through
was spun at 1000xg for 10 min at room temperature with brake off and the supernatant carefully
aspirated (being careful not to disturb the pelleted red cells). The red cells were gently agitated to
resuspend and then lysed by addition of 200 ml ice-cold saponin at 0.015% in PBS (w/v). The cell sus-
pension was incubated on ice for 10 min and then spun at 15,000xg for 10 min at 4˚C with brake off
to pellet the free parasites. The supernatant was slowly aspirated being very careful not to disturb
the pelleted parasites, which were then gently resuspended in 1 ml ice-cold PBS and transferred to a
1.5 ml tube. The parasites were pelleted by centrifugation at 16,000xg for 5 min at 4˚C in a micro-
fuge and two sequential washes were performed with 1 ml ice-cold PBS to remove free globin. After
the final spin, the parasite pellet was resuspended in 1 ml TRIzol, incubated in a 37˚C water bath for
5 min and snap-frozen on dry ice. All samples were stored at  80˚C prior to RNA extraction.
Mosquito challenge
Parasites were isolated from 20 ml whole blood drawn on days 9, 10, and 11 post-infection accord-
ing to the blood challenge protocol, with the following modifications. Red cells were lysed by addi-
tion of 80 ml ice-cold saponin at 0.0075% in PBS (w/v); after the 10 min incubation on ice, free
parasites were then pelleted by centrifugation at 18,000xg for 20 min at 4˚C with brake off.
Inoculum
Two samples of the inoculum used for blood challenge were prepared independently for RNA-
sequencing to provide technical replicates. For each sample, 1 ml of the pre-diluted inoculum (esti-
mated to contain 1000 parasites ml 1 in 0.9% saline) was transferred to a 1.5 ml tube; infected red
cells were pelleted by centrifugation at 1000xg for 5 min at room temperature and (after removal of
the supernatant) resuspended in 1 ml TRIzol. The samples were carefully mixed, incubated in a 37˚C
water bath for 5 min and then snap-frozen on dry ice.
In vitro cultured ring-stage parasites
Two mock samples were prepared using in vitro cultured parasites (clone 3D7) to test the sensitivity
of our ultra-low input methodology for parasite RNA-sequencing. Briefly, parasites were cultured
and synchronised to ring-stage using 5% sorbitol, and the first mock sample was prepared by spiking
2000 parasites into 50 ml whole blood (40 parasites ml 1). The second mock sample was prepared
by spiking 8000 parasites into 20 ml whole blood (400 parasites ml 1). These parasite densities were
chosen to represent the likely burden in the first and second blood cycle after liver egress in
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volunteers infected by mosquito bite (Roestenberg et al., 2012). Parasites were isolated from these
mock samples according to the mosquito challenge protocol above.
Parasite RNA extraction and depletion of globin and ribosomal RNA
Samples were thawed at room temperature and 200 ml bromochloropropane was added; samples
were then vortexed, incubated for 3 min at room temperature and centrifuged at 12,000xg for 15
min at 4˚C. 500 ml of the aqueous phase was transferred to a 1.5 ml tube and diluted 1:1 with abso-
lute ethanol. RNA purification was then carried out using the RNA Clean and Concentrator kit, as
per the manufacturer’s instructions (Zymo Research). RNA was eluted in 14 ml DEPC-treated water
and quantified by nanodrop; quality was assessed using the Agilent 2100 Bioanalyzer with RNA
6000 pico chips. A RIN value above 7.0 was accepted as sufficiently high-quality RNA for down-
stream steps. Samples were then DNase-treated and depleted of globin and ribosomal RNA with
the Globin-Zero Gold kit (Illumina), according to the manufacturer’s instructions. For samples with
less than 1 mg RNA (the recommended starting material) reagent volumes were downscaled for low-
input methodology (as described in the kit). After removal of globin and ribosomal RNA, the remain-
ing RNA was precipitated overnight at 4˚C in 600 ml absolute ethanol, 18 ml sodium acetate (3M),
and 2 ml linear acrylamide (5 mg/ml). The RNA was then pelleted by centrifugation at 12,000xg for
20 min at 4˚C and washed two times with 75% ethanol. Samples were air-dried for 5 min and the
RNA was dissolved in 12 ml DEPC-treated water by heating to 65˚C for 5 min. RNA was stored at
 80˚C prior to cDNA synthesis and amplification.
Parasite RNA-sequencing and data processing
Blood challenge
Double-stranded cDNA was synthesised from 2 ml parasite RNA using the Smart-Seq2 protocol
described by Picelli et al., 2013 and modified for use with low-input P. falciparum RNA (Reid et al.,
2018). cDNA was amplified with 25 cycles of PCR using the KAPA HiFi reaction mix and ISPCR
primer, and purified with Agencourt AMPure XP beads at a 1:1 DNA to bead ratio. Indexed
sequencing libraries were constructed from 500 ng of cDNA with no further PCR amplification.
cDNA was sheared to 400–600 bp with a Covaris sonicator and libraries prepared using the NEB-
Next Ultra DNA library prep kit, according to the manufacturer’s instructions. Libraries were pooled
and run on two separate lanes of distinct Illumina HiSeq v4 flowcells to produce 75 bp paired-end
reads. Read counts per gene were quantified against the P. falciparum v3 transcript sequences
(Böhme et al., 2019) using Kallisto v0.42.3 (Bray et al., 2016). The index was built using default
parameters and quantification was performed with -t 12 -b 0.
Mosquito challenge
Double-stranded cDNA was synthesised and amplified exactly as described for blood challenge,
with the exception that the number of PCR cycles was reduced to 20. Indexed sequencing libraries
were prepared from 1 ng cDNA with the Nextera XT library kit (Illumina), as per the manufacturer’s
instructions. One ml of each undiluted library was run on the Agilent bioanalyzer high sensitivity DNA
chip for quantification and quality assessment, and all libaries were pooled and run on a single lane
of an Illumina Hiseq v4 flowcell. Read counts per gene were quantified against the P. falciparum v3
transcript sequences using Kallisto v0.42.3, as above. The index was built using default parameters
and quantification was performed with -t 12 -b 0.
Analysis of parasite var and rifin expression
For every volunteer infected by mosquito bite, read counts were pooled from days 9, 10, and 11
post-infection to generate a comprehensive parasite transcriptome 2–3 cycles after liver egress. The
two inoculum samples (blood challenge) were not pooled and thus provide technical replicates of a
single biological sample. Data from the mosquito and blood challenge studies were merged and
rlog values (blind=TRUE) were calculated across the entire dataset using DESeq2 (Love et al.,
2014); these values were then used to generate heatmaps of expression intensity. Sub-family classifi-
cations for the 62 var genes were determined from PlasmoDB (Warrenfeltz et al., 2018 based on
Rask et al., 2010) and 158 rifin genes were identified from the same database. Heatmaps were
drawn using pheatmap, clustered with hclust. To generate pie charts of var gene sub-family
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expression we summed FPKM-normalised (Fragments Per Kilobase per Million mapped reads) read
counts for each var gene sub-family for each volunteer. Genes with a summed FPKM of <1 in any
given sample were excluded for that sample and plots were drawn using matplotlib in Python. To
examine reads mapping across var gene introns, we followed the protocol outlined in Reid et al.,
2018. Briefly, we generated a HISAT2 (v2.0.0-beta) index of the P. falciparum v3 genome sequence
using default parameters and mapped reads with parameters -max-intronlen 5000 p 12 (Kim et al.,
2015). We identified reads overlapping annotated var genes using bedtools intersect (Quinlan and
Hall, 2010). We then selected reads with an N in the CIGAR string, indicating a split read. We
counted only those reads that were split exactly over the intron of a var gene. We called expression
for a var gene where there were at least two reads mapping over the intron; read counts were then
converted to logs of Counts Per Million (CPM) using the total number of reads mapping to all other
features and the heatmap was drawn using pheatmap.
Calling differentially expressed parasite genes
To determine whether any parasite genes were differentially expressed between volunteers with dif-
ferent clinical outcomes after blood challenge, we used DESeq2 (Love et al., 2014) to compare par-
asite gene expression profiles from inflammatory volunteers (n = 8) versus the rest (unresponsive
and suppressor, n = 4). In the same way, we used DESeq2 to compare parasite gene expression pro-
files between the inoculum samples (n = 2) and all volunteer samples (n = 12) after blood challenge.
Accession numbers
. Blood challenge human microarray dataset (NCBI GEO): GSE132050
. Mosquito challenge human RNA-sequencing dataset (EBI EGA): EGAS00001003766
. Parasite RNA-sequencing dataset (blood and mosquito challenge) (EBI ENA): PRJEB33557
. Blood challenge metabolomics dataset (MetaboLights): MTBLS1188
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Declaration of Helsinki 2008 and in full conformity with the ICH guidelines for Good Clinical Practice
(GCP). Written informed consent was given by all volunteers and blood donors.
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Additional files
Supplementary files
. Supplementary file 1. Demographics of volunteers infected by blood or mosquito challenge;
includes genetic and non-genetic variables known to influence human immune variation in vitro.
Classification of volunteers by host response after blood challenge is described in the results and
methods.
. Supplementary file 2. Three metrics that measure the magnitude of the human immune response
to blood challenge. [1] The mean variance of the top 50 most variable protein-coding genes in each
volunteer. [2] The Euclidean distance travelled during principal component analysis of the 517-gene
superset. [3] The number of differentially expressed genes at diagnosis in each group. Note that
uninfected control volunteers set a threshold for baseline variation in gene expression through time;
a Mann Whitney test was then used to support the observation that unresponsive volunteers were
comparable to uninfected controls. Classification of volunteers by host response after blood chal-
lenge is described in the results and methods.
. Supplementary file 3. List of the 2028 differentially expressed genes identified in inflammatory vol-
unteers at diagnosis (compared to pre-infection samples). These data underpin the gene ontology
network in Figure 2a.
. Supplementary file 4. List of the 217 significantly enriched GO terms identified in inflammatory vol-
unteers at diagnosis. GO terms are arranged into their functional groups and groups are ordered by
size. The leading GO term in the top 12 functional groups is highlighted in red. On sheet 2, we high-
light the top 20 GO terms as ordered by p value.
. Supplementary file 5. List of the 77 differentially expressed genes identified in suppressor volun-
teers at diagnosis (compared to pre-infection samples). These data underpin the heatmap in
Figure 2d.
. Supplementary file 6. List of the 893 genes that were differentially expressed between inflamma-
tory and suppressor hosts at diagnosis. There were no differentially expressed genes between these
volunteers prior to infection (adj p<0.05).
. Supplementary file 7. Rlog expression values of the 117-gene superset in whole blood after mos-
quito challenge. These data underpin the heatmap in Figure 2—figure supplement 1a. On sheet
two we highlight the volunteers in which EdgeR identified these genes as differentially expressed.
And on sheet three we look at the 21 genes that were most upregulated in inflammatory volunteers
after blood challenge.
. Supplementary file 8. List of the 44 significantly enriched GO terms identified in the 117-gene
superset. GO terms are arranged into their functional groups and groups are ordered by size. On
sheet two we highlight the top 20 GO terms as ordered by p value.
. Transparent reporting form
Data availability
Microarray data have been deposited in NCBI GEO, accession code GSE132050 (blood challenge
human microarray dataset). Sequencing data have been deposited in EBI EGA, accession code EGA
S00001003766 (mosquito challenge human RNA-seq dataset) and EBI ENA, accession code
PRJEB33557 (parasite RNA-seq dataset (blood and mosquito challenge)). Metabolomics data have
been deposited in MetaboLights, accession code MTBLS1188 (blood challenge metabolomics data-
set). Information on clinical trials are available at ClinicalTrials.gov using accession codes
NCT02044198 and NCT02905019.
The following datasets were generated:
Author(s) Year Dataset title Dataset URL
Database and Identifier
Milne K, Ivens A,
Draper SJ, Rowe A,
2020 Longitudinal profiling of the
human immune response to
https://www.ncbi.nlm.
nih.gov/geo/query/acc.
NCBI Gene Expression
Omnibus, GSE132050
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Spence PJ Plasmodium falciparum cgi?acc=GSE132050
Milne K, Reid AJ,
Lotkowska ME,
Sankaranarayanan
G, Sanders MJ, Hill
AV, Berriman M,
Rowe A, Spence PJ
2020 Immune variation leads to
diverse outcomes in human
malaria
https://www.ebi.ac.uk/
ega/datasets/
EGAD00001005790
EBI EGA accession code,
EGAS00001003766
Milne K, Reid AJ,
Lotkowska ME,
Sankaranarayanan
G, Sanders MJ, Hill
AV, Berriman M,
Draper SJ, Rowe A,
Spence PJ
2020 Diverse outcomes of
controlled human malaria
infection originate from host-
intrinsic immune variation and
not var gene switching
https://www.ebi.ac.uk/
ena/browser/view/
PRJEB33557
ENA accession code ,
PRJEB33557
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TK, Thompson J, Matthews KR. 2019. Oligopeptide signaling through TbGPR89 drives trypanosome quorum
sensing. Cell 176:306–317. DOI: https://doi.org/10.1016/j.cell.2018.10.041, PMID: 30503212
Sallusto F, Cassotta A, Hoces D, Foglierini M, Lanzavecchia A. 2018. Do memory CD4 T cells keep their Cell-
Type programming: plasticity versus fate commitment? T-Cell heterogeneity, plasticity, and selection in
humans. Cold Spring Harbor Perspectives in Biology 10:a029421. DOI: https://doi.org/10.1101/cshperspect.
a029421, PMID: 28432133
Scheltema RA, Jankevics A, Jansen RC, Swertz MA, Breitling R. 2011. PeakML/mzMatch: a file format, Java
library, R library, and tool-chain for mass spectrometry data analysis. Analytical Chemistry 83:2786–2793.
DOI: https://doi.org/10.1021/ac2000994, PMID: 21401061
Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD,
Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie
E, Moyle S, et al. 2012. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1:
assessment of efficacy against mosquito bite challenge in humans. Molecular Therapy 20:2355–2368.
DOI: https://doi.org/10.1038/mt.2012.223, PMID: 23089736
Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. 2006. XCMS: processing mass spectrometry data for
metabolite profiling using nonlinear peak alignment, matching, and identification. Analytical Chemistry 78:779–
787. DOI: https://doi.org/10.1021/ac051437y, PMID: 16448051
Smith JD, Rowe JA, Higgins MK, Lavstsen T. 2013. Malaria’s deadly grip: cytoadhesion of Plasmodium
falciparum-infected erythrocytes. Cellular Microbiology 15:1976–1983. DOI: https://doi.org/10.1111/cmi.12183,
PMID: 23957661
Spaulding E, Fooksman D, Moore JM, Saidi A, Feintuch CM, Reizis B, Chorro L, Daily J, Lauvau G. 2016. STING-
Licensed macrophages prime type I IFN production by plasmacytoid dendritic cells in the bone marrow during
severe plasmodium yoelii malaria. PLOS Pathogens 12:e1005975. DOI: https://doi.org/10.1371/journal.ppat.
1005975, PMID: 27792766
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